Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tharimmune ( (THAR) ) is now available.
On July 31, 2025, Tharimmune, Inc. completed a private placement agreement with accredited investors, resulting in the issuance and sale of common stock and warrants. The transaction, which closed after meeting customary conditions, is expected to generate gross proceeds of $1,225,003. The company plans to use the net proceeds for clinical development and working capital, with President Street Global serving as the exclusive placement agent.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Average Trading Volume: 52,135
Technical Sentiment Signal: Sell
Current Market Cap: $5.66M
For detailed information about THAR stock, go to TipRanks’ Stock Analysis page.